Implications of Efavirenz for Neuropsychiatry: A Review

REFERENCES

• Aarnoutse, R. E., Grintjes, K. J. T., Telgt, D. S. C., Stek, M., Hugen, P. W. H., Reiss, P., (2002). The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clinical Pharmacology & Therapeutics, 71, 57–67.
   PubMed Web of Science ®Google Scholar
• Aksenov, M., Aksenov, M., Butterfiel, D. A., & Markesbery, W. R. (2000). Oxidative modification of creatine kinase BB in Alzheimer's disease brain. Journal of Neurochemistry, 74, 2520–2527.
   PubMed Web of Science ®Google Scholar
• Albert, K. A., Hemmings, H. C., Adamo, A. I., Potkin, S. G., Akbarian, S., Sandman, C. A., (2002). Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Archives of Gerontology Psychiatry, 59, 705–712.
   PubMed Web of Science ®Google Scholar
• Almond, L. M., Hoggard, P. G., Edirisinghe, D. E., Khoo, S. H., & Back, D. J. (2005). Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 56, 738–744.
   PubMed Web of Science ®Google Scholar
• Antoniou, T., & Tseng, A. L. (2002). Interactions between recreational drugs and antiretroviral agents. Annals of Pharmacotherapy, 36, 1596–1613.
   Google Scholar
• Araújo, A. A. S., & Alves, I. R. A. (2002). Terapêutica Anti-retroviral: Situação atual e perspectivas da quimioterapia de combate ao HIV/AIDS. Cadernos—Centro Universitário São Camilo, 8, 96–108.
   Google Scholar
• Arendt, G., Nocker, D., Von Giesen, H. J., & Nolting, T. (2007). Neuropsychiatric side effects of efavirenz therapy. Expert Opinion on Drug Safety, 6, 147–154.
   PubMed Web of Science ®Google Scholar
• Bickel, M., Stephan, C., Rottmann, C., Carlebach, A., Haberl, A., Kurowski, M., (2005). Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. Scandinavian Journal of Infectious Diseases, 37, 520–252.
   PubMed Web of Science ®Google Scholar
• Blanch, J., Corbella, B., Garcia, F., Parellada, E., & Gatell, J. M. (2001). Manic syndrome associated with efavirenz overdose. Clinical Infectious Diseases, 15, 270–271.
   Google Scholar
• Blanch, J., Martínez, E., Rousaud, A., José-Luis, B., García-Viejo, M. A., Peri, J. M., (2001). Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. Journal of Acquired Immune Deficiency Syndromes, 27, 336–343.
   PubMed Web of Science ®Google Scholar
• Clercq, E. (2001). Antiviral drugs: Current state of the art. Journal of Clinical Virology, 22, 73–89.
   PubMed Web of Science ®Google Scholar
• Date, H. L., & Fisher, M. (2009). HIV infection. In R. Walker and C. Whittlesea (eds.), Clinical Pharmacy and Therapeutics, 4th ed. London: Churchill Livingstone Elsevier, 568–598.
   Google Scholar
• David, S., Shoemaker, M., & Haley, B. E. (1998). Abnormal properties of creatine kinase in Alzheimer's disease brain: Correlation of reduced enzyme activity and active site photolabeling with aberrant cytosol-membrane partitioning. Molecular Brain Research, 54, 276–287.
   PubMedGoogle Scholar
• Daya, S., Nonaka, K. O., Buzzel, G. R., & Reiter, J. R. (1989). Heme precursor 5-aminolevulinic acid alters brain tryptophan and serotonin levels without changing pineal serotonin and melatonin concentrations. Journal of Neuroscience Research, 23, 304–309.
   PubMed Web of Science ®Google Scholar
• de la Garza, C. L. S., Paoletti-Duarte, S., García-Martín, C., & Gutiérrez-Casares, J. R. (2001). Efavirenz-induced psychosis. AIDS, 15, 1911–1912.
   PubMedGoogle Scholar
• Dursun, S. M., Blackburn, J. R., & Kutcher, S. P. (2001). An exploratory approach to the serotonergic hypothesis of depression: Bridging the synaptic gap. Medical Hypotheses, 56, 235–243.
   PubMedGoogle Scholar
• Efavirenz. (2009). Sustiva. Rhodes, Greece: Cerner Multum.
   Google Scholar
• Fumaz, C. R., Munõz-Moreno, J. A., Moltó, J., Negredo, E., Ferrer, M. J. M. A., Sirera, J., (2005). Long-term neuropsychiatric disorders on efavirenz-based approaches: Quality of life, psychologic issues, and adherence. Journal of Acquired Immune Deficiency Syndromes, 38, 560–565.
   PubMed Web of Science ®Google Scholar
• Graeff, F. G., Guimaraes, F. S., De Andrade, T. G. C. S., & Deakin, J. F. W. (1996). Role of 5-HT in stress, anxiety, and depression. Pharmacology, Biochemistry, and Behavior, 54, 129–141.
   PubMed Web of Science ®Google Scholar
• Gutiérrez, F., Navarro, A., Padilla, S., Antón, R., Masiá, M., Borrás, J., (2005). Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clinical Infectious Diseases, 41, 1648–1653.
   PubMed Web of Science ®Google Scholar
• Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. M., Gulick, R. M., (2004). Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trial Group study. AIDS, 18, 2391–400.
   PubMed Web of Science ®Google Scholar
• Hariparsad, N., Nallani, S. C., Sane, R. S., Buckley, D. J., Buckley, A. R., & Desai, P. B. (2004). Induction of CYP3A4 by efavirenz in primary human hepatocytes: Comparison with rifampin and phenobarbital. Journal of Clinical Pharmacology, 44, 1273–1281.
   PubMed Web of Science ®Google Scholar
• Hawkins, T., Geist, C., Young, B., Giblin, A., Mercier, R. C., Thornton, K., (2005). Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clinical Trials, 6, 187–196.
   PubMed Web of Science ®Google Scholar
• Hesse, L. M., von Moltke, L. L., Shader, R. I., & Greenblatt, D. J. (2001). Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion. Drug Metabolism and Disposition, 29, 100–102.
   PubMed Web of Science ®Google Scholar
• Jena, A., Sachdeva, R. K., Sharma, A., & Wanchu, A. (2009). Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: A 24-week prospective study. Journal of the International Association of Physicians in AIDS Care, 8, 318–322.
   Google Scholar
• Kato, T., & Kato, N. (2000). Mitochondrial dysfunction in bipolar disorder. Bipolar Disorders, 2, 180–190.
   PubMed Web of Science ®Google Scholar
• Konradi, C., Eaton, M., MacDonald, M. L., Walsh, J., Benes, F. M., & Heckers, S. (2004). Molecular evidence for mitochondrial dysfunction in bipolar disorder. Archives of Gerontology Psychiatry, 61, 300–308.
   PubMed Web of Science ®Google Scholar
• Langmann, P., Schirmer, D., Vath, T., Zilly, M., & Klinker, H. (2001). High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy. Journal of Chromatography. B, Biomedical Sciences and Applications, 755, 151–156.
   PubMed Web of Science ®Google Scholar
• Leonard, B. E., & Myint, A. (2006). Inflammation and depression: Is there a causal connection with dementia? Neurotoxicity Research, 10, 149–160.
   PubMed Web of Science ®Google Scholar
• Liu, P., Foster, G., LaBadie, R. R., Gutierrez, M. J., & Sharma, A. (2005). Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy subjects. Clinical Pharmacology & Therapeutics, 77, 40.
   Google Scholar
• Lochet, P., Peyriere, H., Lotthé, A., Mauboussin, J. M., Delmas, B., & Reynes, J. (2003). Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Medicine, 4, 62–66.
   PubMedGoogle Scholar
• Luin van, M., Brouwer, A. M., van der Ven, A., de Lange, W., van Schaik, R. H. N., & Burger, D. M. (2009). Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin. AIDS, 23, 742–744.
   PubMedGoogle Scholar
• Maes, M., Meltzer, H. Y., Scharpe, S., Bosmans, E., Suy, E., De Meester, I., (1993). Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Research, 49, 151–165.
   PubMed Web of Science ®Google Scholar
• Manji, H. K., Drevets, W. C., & Charney, D. S. (2001). The cellular neurobiology of depression. Nature Medicine, 7, 541–547.
   PubMed Web of Science ®Google Scholar
• Marwaha, A. (2008). Getting High on HIV Drugs in S Africa. Retrieved 10 August 2010, from http://news.bbc.co.uk/2/hi/africa/7768059.stm
   Google Scholar
• Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., & Buclin, T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15, 71–75.
   PubMed Web of Science ®Google Scholar
• Ministério da Saúde (Brasil) & Programa Nacional DST/AIDS. (2004). Recomendações para terapia anti-retroviral em adultos e adolescentes infectados pelo HIV 2004. Brasília, Brazil: Ministério da Saúde.
   Google Scholar
• Monshouwer, M., Witkamp, R. F., Nijmeijer, S. M., Van Amsterdam, J. G., & Van Miert, A. S. J. P. A. M. (1996). Supression of cytochrome P450 and UDP glucuronosyl transferase-dependent enzyme activies by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicology and Applied Pharmacology, 137, 237–244.
   PubMed Web of Science ®Google Scholar
• O’Mahony, S. M., Myint, A., Steinbusch, H., & Leonard, B. E. (2005). Efavirenz induces depressive like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation, 12, 293–298.
   PubMed Web of Science ®Google Scholar
• Park-Wyllie, L. Y., & Antoniou, T. (2003). Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: A case series. AIDS, 17, 638–640.
   PubMed Web of Science ®Google Scholar
• Paterson, D. L., Swindells, S., Brester, M., & Vergis, E. N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21–30.
   PubMed Web of Science ®Google Scholar
• Patroclo, M. A. A., & Medronho, R. A. (2007). Evolução da contagem de células T CD4+ de portadores de AIDS em contextos socialmente desiguais. Caderno de Saúde Pública, 23, 1955–1963.
   PubMedGoogle Scholar
• Pérez-Molina, J. A. (2002). Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1, 033 HIV-infected patients. HIV Clinical Trials, 3, 279–286.
   PubMedGoogle Scholar
• Peyriere, H., Mauboussin, J. M., Rouanet, I., Fabre, J., & Reynes, J. (2001). Management of sudden psychiatric disorders related to efavirenz. AIDS, 15, 1323–1324.
   PubMed Web of Science ®Google Scholar
• Piacenti, F. J. (2006). An update and review of antiretroviral therapy. Pharmacotherapy, 26, 1111–1133.
   PubMed Web of Science ®Google Scholar
• Prabakaran, S., Swatton, J. E., Ryan, M. M., Huffaker, S. J., Huang, J. T. J., Griffin, J. L., (2004). Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. Molecular Psychiatry, 9, 684–697.
   PubMed Web of Science ®Google Scholar
• Puzantian, T. (2002). Central nervous system adverse effects with efavirenz: Case report and review. Pharmacotherapy, 22, 930–933.
   PubMed Web of Science ®Google Scholar
• Quereda, C., Corral, I., Moreno, A., Péres-Elias, M. J., Casado, J. L., Dronda, F., (2008). Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV coinfected patients. Journal of Acquired Immune Deficiency Syndromes, 49, 61–63.
   PubMed Web of Science ®Google Scholar
• Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005). Neuropsychiatric adverse effects of interferon-α: Recognition and management. CNS Drugs, 19, 105–123.
   PubMed Web of Science ®Google Scholar
• Rihs, T. A., Begley, K., Smith, D. E., Sarangapany, J., Callaghan, A., Kelly, M., (2006). Efavirenz and chronic neuropsychiatric symptoms: A cross-sectional case control study. HIV Medicine, 7, 544–548.
   PubMed Web of Science ®Google Scholar
• Robbins, K. E., Lemey, P., Pybus, O. G., Jaffe, H. W., Youngpairoj, A. S., Brown, T. M., (2003). Human immunodeficiency virus type 1 epidemic: Date of origin, population history, and characterization of early strains. Journal of Virology, 11, 59–66.
   Google Scholar
• Romão, P. R. T., Lemos, J. C., Moreira, J., de Chaves, G., Moretti, M., Castro, A. A., (2009). Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. Neurotoxicity Research. Accessed 10 August 2010, DOI: http://dx.doi.org/10.1007/si2640-009-9141-y, ISSN1029-8428. [Epub ahead of print].
   PubMedGoogle Scholar
• Rotger, M., Colombo, S., Furrer, H., Bleiber, G., Buclin, T., Lee, B. L., (2005). Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV infected patients. Pharmacogenetics and Genomics, 15, 1–5.
   PubMedGoogle Scholar
• Rothermundt, M., Missler, U., Arolt, V., Peters, M., Leadbeater, J., Wiesmann, M., (2001). Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Molecular Psychiatry, 6, 445–449.
   PubMed Web of Science ®Google Scholar
• Sacktor, N., Lyles, R. H., Skolasky, R., Kleeberger, C., Selnes, O. A., Miller, E. N., (2001). HIV-associated neurologic disease incidence changes: Multicenter AIDS cohort study, 1990–1998. Neurology, 56, 257–260.
   PubMed Web of Science ®Google Scholar
• Sanchez, H. V., & Gutierrez, R. F. (2008). Toxicogenetics of antiretroviral treatment (II): Neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs. Enfermedades Infecciosas y Microbiologia Clinica, 6, 24–33.
   Google Scholar
• Sargent, P. A., Kjaer, K. H., Bench, C. J., Rabiner, E. A., Messa, C., Meyer, J., (2000). Brain serotonin1A receptor binding measured by positron emission tomography with [11C] WAY-100635: Effects of depression and antidepressant treatment. Archives of General Psychiatry, 57, 174–180.
   PubMed Web of Science ®Google Scholar
• Skidmore-Roth, L. (2009). Mosby's Drug Guide of Nurses, 8th ed. St. Louis, MO: Mosby Elsevier, 346 pp.
   Google Scholar
• Steffens, D. C., Plassman, B. L., Helms, M. J., Welsh-Bohmer, K. A., Saunders, A. M., & Breitner, J. C. (1997). A twin study of late-onset depression and apolipoprotein E4 as risk factors for Alzheimer's disease. Biological Psychiatry, 41, 851–856.
   PubMed Web of Science ®Google Scholar
• Streck, E. L., Amboni, G., Scaini, G., Di-Pietro, P. B., Rezin, G. T., Valvassori, S. S., (2008). Brain creatine kinase activity in an animal model of mania. Life Sciences, 82, 424–429.
   PubMedGoogle Scholar
• Streck, E. L., Scaini, G., Rezin, G. T., Moreira, J., Fochesato, C. M., & Romão, P. R. T. (2008). Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metabolic Brain Disease, 23, 485–492.
   PubMed Web of Science ®Google Scholar
• Tomimoto, H., Yamamoto, K., Homburger, H. A., & Yanagihara, T. (1993). Immunoelectron microscopic investigation of creatine kinase BB-isoenzyme after cerebral ischemia in gerbils. Acta Neuropathologica, 86, 447–455.
   PubMed Web of Science ®Google Scholar
• Treisman, G. J., & Kaplan, A. I. (2002). Neurologic and psychiatric complications of antiretroviral agents. AIDS, 16, 1201–1215.
   PubMed Web of Science ®Google Scholar
• Tsuchiya, K., Gatanaga, H., Tachikawa, N., Teruya, K., Kikuchi, Y., Yoshino, M., (2004). Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochemical and Biophysical Research Communications, 319, 1322–1326.
   PubMed Web of Science ®Google Scholar
• Turner, B. G., & Summers, M. F. (1999). Structural biology of HIV. Journal of Molecular Biology, 285, 1–32.
   PubMed Web of Science ®Google Scholar
• von Giesen, H. J., Köller, H., Theisen, A., & Arendt, G. (2002). Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes, 29, 363–367.
   PubMed Web of Science ®Google Scholar
• Wallimann, T., Wys, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992). Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The “phosphocreatine circuit” for cellular energy homeostasis. Biochemical Journal, 281, 21–40.
   PubMed Web of Science ®Google Scholar
• Wande, A. N. (1994). Handbook of Pharmaceutical excipients, 2th ed. Washington, DC: American Pharmaceutical Association.
   Google Scholar
• Zheve, G. T. (2007). Neuroprotective Mechanisms of Nevirapine and Efavirenz in Model of Neurodegeneration. Rhodes, Greece: Rhodes University.
   Google Scholar